Skip to main content
Finally meeting @synovialjoints after 3 years of reporting together for @RheumNow!

Some serious interviews on AxSPA goi

Aurelie Najm

2 years 9 months ago
Finally meeting @synovialjoints after 3 years of reporting together for @RheumNow! Some serious interviews on AxSPA going on at the booth, I won’t reveal who was his guest: you’ll have to find out on https://t.co/YxAt6H2Qza https://t.co/dQHPw3pS3d
What if you have a first degree relative with ankylosing spondylitis?
100 pts w/o previous rheum dx w/ 1st degree AS rel

Robert B Chao, MD

2 years 9 months ago
What if you have a first degree relative with ankylosing spondylitis? 100 pts w/o previous rheum dx w/ 1st degree AS relative 17% had MRI sacroiliitis 25% met classification criteria 14% dx with AS @RheumNow #ACR23 Abs#1403 https://t.co/Z0juhRnLki
15-year results from Abs #1389 at #ACR23 found only low back pain to be predictor of spinal radiographic progression in

Dr. Rachel Tate

2 years 9 months ago
15-year results from Abs #1389 at #ACR23 found only low back pain to be predictor of spinal radiographic progression in axSpA pts. Mean and median progression changes by mSASSS per year less in this cohort than previously documented. https://t.co/VKTEZWvH7f @rheumnow https://t.co/6sjPrcw2dD
Biologics are working for ankylosing spondylitis, even in reducing cardiovascular mortality!
Large retrospective study o

Robert B Chao, MD

2 years 9 months ago
Biologics are working for ankylosing spondylitis, even in reducing cardiovascular mortality! Large retrospective study of over 4k pts over 20 years showed decrease in CV mortality from 34% in 1999 to 21% in 2020 @RheumNow #ACR23 Abs#1399 #ACRbest https://t.co/wKCIXHza0v
Although general agreement that dz activity monitoring is important, implementation of AS/axSpA guideline recommendation

Dr. Rachel Tate

2 years 9 months ago
Although general agreement that dz activity monitoring is important, implementation of AS/axSpA guideline recommendations is lacking. Guideline uptake & implementation should be considered in future updates of axSpA/AS tx recs. #ACR23 Abs #1385 https://t.co/RsyDppe3aR @rheumnow https://t.co/xxZ9pa77h9
Defining accuracy of Administrative Codes for Autoinflammatory Syndromes is important to lay groundwork!
AOSD, SJIA, B

Bella Mehta bella_mehta

2 years 9 months ago
Defining accuracy of Administrative Codes for Autoinflammatory Syndromes is important to lay groundwork! AOSD, SJIA, BD, FMF, CAPS and SAPHO-CNO ICD codes validated as Autoinflammatory syndromes (AIS)- PPV low @RheumNow #ACR23 #abst1129 https://t.co/XqIrUmUCVc
Never forget the physical toll that RA has taken on our patients.

RA pts in BC🇨🇦, dx 1996-2008 (n=13367)

Frailit

David Liew drdavidliew

2 years 9 months ago
Never forget the physical toll that RA has taken on our patients. RA pts in BC🇨🇦, dx 1996-2008 (n=13367) Fraility score 5y post-dx: twice as likely to be frail vs matched controls I would love to see those dx 2008-2018 Have biologics moved the needle? #ACR23 ABST1275 @RheumNow https://t.co/gMXo5Pp1qA
Upcoming Plenary II session
Ab#1584 on Bactrim for GPA pts on RTX
Should you use this for prophylaxis after weaning the

Eric Dein

2 years 9 months ago
Upcoming Plenary II session Ab#1584 on Bactrim for GPA pts on RTX Should you use this for prophylaxis after weaning the prednisone? #ACR23 @RheumNow
#ACR23 Abstr#0509 Is sero-ve #Sjogren sero-ve? A study showed promising diagnostic model comprises clinical & novel

Md Yuzaiful Md Yusof

2 years 9 months ago
#ACR23 Abstr#0509 Is sero-ve #Sjogren sero-ve? A study showed promising diagnostic model comprises clinical & novel autoantibodies (DTD2) using whole peptidome array (AUC:74%) to avoid need for lips biopsy in ANA-ve. Need further validation & wider access to this test @RheumNow https://t.co/FmE8AJdMVe
In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC

sheila

2 years 9 months ago
In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al) ⬆️freq AEs: nasopharyngitis & URTI Low EAIRs/100pt yrs for IBD, malignancies & MACE No new safety signals Reassuring data. #ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM
In their cohort, Dr. Jorge reports that SLE pts who used SGLT2i had⬇️risk of MACE(HR 0.69 [95% CI 0.48-0.99]) &

sheila

2 years 9 months ago
In their cohort, Dr. Jorge reports that SLE pts who used SGLT2i had⬇️risk of MACE(HR 0.69 [95% CI 0.48-0.99]) & renal progression(HR 0.71 [95% CI 0.51-0.98]) vs DPP4 use Risk of MACE also⬇️in LN subgrp 🧐💊A potential role of SGLT2i for SLE/LN? #ACR23 ABST1579 @RheumNow #ACRbest https://t.co/Dod8DqRvLo
#ACR23 @RheumNow
SGLT2 inhibitors help CV & renal outcomes, but SLE pts excluded @AprilJorgeMD
ComparedSGLT2 to DPP4

Eric Dein

2 years 9 months ago
#ACR23 @RheumNow SGLT2 inhibitors help CV & renal outcomes, but SLE pts excluded @AprilJorgeMD ComparedSGLT2 to DPP4 inhibs, real world observation emulation study in SLE pts with T2DM Lower incidence of MACE & renal progression Subgroup w LN - risk reduction 10.2 MACE/100 py https://t.co/JpJ0yWNQBe
Excellent start to Plenary II
Should we borrow SGLT2i and DPP4i use from endocrine?
SLE pts who initiated SGLT2 or DPP4:

Robert B Chao, MD

2 years 9 months ago
Excellent start to Plenary II Should we borrow SGLT2i and DPP4i use from endocrine? SLE pts who initiated SGLT2 or DPP4: lower risk of MACE and renal progression @RheumNow #ACR23 Abs#1579 https://t.co/RsaWuetyft
RA peripheral blood mononuclear cells display IFN-gamma signature

Driven by 2 cell subsets: T cells & macrophages

Aurelie Najm

2 years 9 months ago
RA peripheral blood mononuclear cells display IFN-gamma signature Driven by 2 cell subsets: T cells & macrophages IFNg driven transcription factors Increased only in ACPA+ RA Differential biology could inform ACPA stratified therapy ABST1271 @RheumNow #ACR23 https://t.co/EN2noKGupK
Glucocorticoids-free zone in SLE?

For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE

Dr. John Cush RheumNow

2 years 9 months ago
Glucocorticoids-free zone in SLE? For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. #ACR23 https://t.co/sfRhNj6OpZ https://t.co/k6VoG5lKO7
×